№ files_lp_4_process_2_52459
File format: docx
Character count: 4978
File size: 35 KB
Formulary record for documenting the administration schedule, dosages, and patient reactions to allergen immunotherapy injections.
Note:
Prescribing Physician
Vials:
D, E, F
Vaccine Abbreviations:
T, M, G, C, W, D, R, Cr, Mx, Dm
Baseline Measurements:
Peak Flow, Blood Pressure
Health Screen:
Yes/No
Antihistamine Use:
Yes/No
Reactions:
Local (LR), Systemic (SR)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Europe
Topic:
Allergen immunotherapy, allergic asthma, house dust mites
Document Type:
Clinical guideline
Organization / Institution:
European Academy of Allergy and Clinical Immunology (EAACI)
Authors:
I Agache, S Lau, CA Akdis, S Smolinska, M Bonini, O Cavkaytar, B Flood, P Gajdanowicz, K Izuhara, Ö Kalayci, R Mosges, O Palomares, N Papadopoulos, M Sokolowska, E Angier, M Fernandez-Rivas, G Pajno, O Pfaar, G Roberts, D Ryan, G Sturm, R van Ree, EM Varga, R Gerth van Wijk, JJ Yepes – Nuñez, M Jutel
Target Audience:
Healthcare professionals (doctors, researchers, allergy specialists)
Date Approved:
2023
Date of Revisions:
N/A
Year:
Not specified
Region / City:
Not specified
Topic:
Allergen immunotherapy billing and insurance coverage
Document Type:
Template
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare providers, insurance companies
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
Wuhan, China
Topic:
Immunology, Cancer Research, Gene Expression, Immunotherapy
Document Type:
Research Article
Institution:
Wuhan University of Science & Technology, Huazhong University of Science and Technology, Anhui Normal University
Authors:
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Target Audience:
Researchers, Healthcare Professionals, Academics in Immunology and Oncology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Organization:
Society for Immunotherapy of Cancer
Document Type:
Bibliography
Subject:
Cancer Immunotherapy
Focus:
Head and Neck Squamous Cell Carcinoma
Publication Date:
December 17, 2018
Date Range of Literature Search:
December 1, 2013 – December 17, 2018
Search Limits:
Humans, Clinical Trial, Meta-Analysis, Practice Guideline, Randomized Controlled Trial, Review
Therapeutic Agents Covered:
Pembrolizumab, Nivolumab, Cemiplimab, Durvalumab
Biomarkers and Targets:
PD-1, PD-L1, HPV
Total References Identified:
199
Total Duplicates Removed:
42
Total Records in Bibliography:
157
Topics Included:
Immune checkpoint inhibitors, biomarkers, combination immunotherapy, adverse events, toxicity, vaccine, adjuvant and neoadjuvant immunotherapy, rare head and neck cancers
Journal:
World Journal of Gastrointestinal Oncology
Manuscript Number:
80135
Manuscript Type:
Review
Authors:
Ying-Zhe Luo; Hong Zhu
Author Affiliations:
Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Corresponding Author:
Hong Zhu
Funding:
The Key Research Projects of Science and Technology of Sichuan Province (No. 2022YFS0189)
Received:
September 18, 2022
Revised:
February 11, 2023
Accepted:
February 27, 2023
Published Online:
March 15, 2023
Volume and Issue:
Volume 15, Issue 3
Pages:
405-424
DOI:
10.4251/wjgo.v15.i3.405
Publisher:
Baishideng Publishing Group Inc.
Keywords:
Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine
Subject Area:
Oncology; Hepatology; Cancer Immunotherapy
Geographic Context:
Global epidemiology with reference to East and South-East Asia, United States, and Europe
Year:
2026
Region / City:
International / Multiple research institutions
Subject:
Cancer immunotherapy, tumor microenvironment
Document type:
Supplementary scientific data
Institution:
University of Southampton, Genkyotex SA, La Jolla Institute for Allergy & Immunology, University of Toronto, University of Kent
Authors:
Kirsty Ford, Christopher J. Hanley, Massimiliano Mellone, Cedric Szyndralewiez, Freddy Heitz, Philippe Wiesel, Oliver Wood, Maria Machado, Monette Lopez, Anusha-Preethi Ganesan, Chuan Wang, Ankur Chakravarthy, Tim Fenton, Emma V. King, Pandurangan Vijayanand, Christian H. Ottensmeier, Aymen Al-Shamkhani, Natalia Savelyeva, Gareth J. Thomas
Target audience:
Researchers in oncology and immunology
Data type:
Figures, tables, and experimental results
Methods:
Q-PCR, immunofluorescence, IHC, RNA sequencing, gene network analysis
Experimental models:
Murine syngeneic tumors, TC1, MC38, 4T1, BALBneuT breast tumors
Treatment tested:
NOX4 inhibition, TGF-β1 inhibition, αPD-1, αCTLA-4, macrophage depletion
Key focus:
CAF-mediated CD8 T-cell exclusion, tumor growth modulation, immunotherapy response
Supplementary content:
Figures S1–S6, Tables S1–S2
Year:
2022
Region / City:
Daejeon, Republic of Korea
Subject:
Pharmacology, Immunotherapy, Herbal Medicine
Document Type:
Supplementary Research Document
Institution:
Chungnam National University, Korea Institute of Oriental Medicine
Authors:
Sung-yoon Yang, Jin-Mu Yi, Jaemoo Chun, Seongwon Park, Tham Thi Bui, Hwi-yeol Yun, Jung-woo Chae, Mi-Kyung Jeong
Target Audience:
Researchers in pharmacology and immunotherapy
Methodologies:
LC-MS/MS, ELISA, Cytokine Assay
Compounds Analyzed:
Bojungikki-tang components, anti-PD-L1 antibody
Study Model:
Mouse serum samples
Purpose:
Assessment of pharmacokinetic interactions and biomarker quantification
Year:
2026
Region / City:
Shanghai, China
Topic:
Cancer immunotherapy, ovarian cancer
Document Type:
Research article with supplementary materials
Institution:
Fudan University, Obstetrics and Gynecology Hospital; Shanghai Cancer Center
Authors:
Kankan Cao, Guodong Zhang, Moran Yang, Yiying Wang, Mengdi He, Chen Zhang, Yan Huang, Jiaqi Lu, Haiou Liu
Target Audience:
Biomedical researchers, oncologists
Experimental Models:
Mouse xenografts and isografts (OVCAR-5, SKOV3, HM1, ID8agg)
Methodologies:
RNA sequencing, CCK-8 proliferation assay, BrdU incorporation, colony formation assay, migration assay, Random Forest analysis, scRNA-seq
Therapeutic Interventions:
St3gal3 inhibition, macrophage depletion, CXCR3 blocking, α2,3 sialylation targeting, dual immune checkpoint blockade (anti-PD-1, anti-CTLA-4)
Data Repositories:
GEO accession numbers GSE213219, GSE224856, GSE158937, GSE147082
Supplementary Materials:
Figures S1–S14, detailed methods, references
Note:
Year
Topic:
Vaccination Consent
Document Type:
Consent Form
Target Audience:
Patients, Healthcare Providers
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / City:
London
Topic:
Neonatal BCG vaccination program
Document Type:
Protocol
Organization / Institution:
NHSE
Author:
Alice Waters
Target Audience:
Healthcare professionals involved in neonatal care and immunization
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
September 2025
Year:
2023
Region / City:
N/A
Subject:
Vaccination
Document Type:
Medical Guidelines
Organization / Institution:
Merck
Author:
N/A
Target Audience:
Healthcare professionals
Effective Period:
N/A
Approval Date:
07/13/2015
Revision Dates:
07/13/2015, 11/15/2015, 06/2016, 04/2023, 08/2024
Year:
2025
Region / city:
United Kingdom
Subject:
COVID-19 vaccination
Document type:
Protocol
Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare providers involved in COVID-19 vaccination
Period of validity:
1 October 2025 – 31 January 2026
Approval date:
12 September 2025
Note:
Revision history
Year:
2025
Region / city:
[insert local health board name]
Theme:
Vaccination
Document type:
Patient Group Direction (PGD)
Authorising organisation:
NHS Wales
Target audience:
Healthcare professionals (Registered)
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
07 August 2025
Amendment date:
30 June 2025
Review date:
01 July 2026
Expiry date:
31 March 2026
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / city:
Global
Topic:
Vaccine Policy, Maternal Health, Group B Streptococcus
Document type:
WHO Guidance
Institution:
World Health Organization (WHO)
Author:
WHO ECVP
Target audience:
Policymakers, Vaccine Developers, Public Health Authorities
Period of validity:
Ongoing
Approval date:
March 11, 2025
Date of changes:
Not specified
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024